Idera Pharmaceuticals, Inc. (IDRA) Misses Q2 EPS by 1c

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) reported Q2 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $38 thousand, versus $29 thousand reported last year.

For earnings history and earnings-related data on Idera Pharmaceuticals, Inc. (IDRA) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c